Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADXS
CUSIPN/A
Phone609-452-9813
Debt
Debt-to-Equity RatioN/A
Current Ratio3.47
Quick Ratio3.47
Price-To-Earnings
Trailing P/E Ratio-0.71
Forward P/E Ratio-1.20
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.03 million
Price / Sales7.13
Cash FlowN/A
Price / CashN/A
Book Value$0.86 per share
Price / Book1.90
Profitability
EPS (Most Recent Fiscal Year)($2.31)
Net Income$-93,430,000.00
Net Margins-1,041.73%
Return on Equity-168.35%
Return on Assets-99.50%
Miscellaneous
Employees108
Outstanding Shares52,620,000
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis, Inc. (NASDAQ:ADXS) posted its quarterly earnings data on Monday, March, 12th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.06. The biotechnology company had revenue of $2.06 million for the quarter, compared to analysts' expectations of $3.03 million. Advaxis had a negative net margin of 1,041.73% and a negative return on equity of 168.35%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
3 analysts have issued 1-year price objectives for Advaxis' stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate Advaxis' stock price to reach $3.3333 in the next year. View Analyst Ratings for Advaxis.
What are Wall Street analysts saying about Advaxis stock?
Here are some recent quotes from research analysts about Advaxis stock:
- 1. HC Wainwright analysts commented, "We base our $20 price target on probability-adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and our estimated fully diluted year- end 2018 net cash of $2.17/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x. We use a 25% discount rate for the pipeline, which includes CCX140, CCX872 and avacopan for HS, as it is above the marketed products discount rate due to development risks but within the typical range of 15-25% for products in development. We project revenues of $72M for avacopan in AAV in 2021, growing to $1.4B in 2028. For avacopan in C3G, we estimate revenues of $10M in 2024, increasing to $124M in 2028." (6/8/2018)
- 2. Cantor Fitzgerald analysts commented, "Multiple inflection points expected in 2018, including an update on the AIM2CERV Phase III study and potential preliminary data from Part B of the Phase I/II study of ADXS-PSA in combination with Keytruda." (9/25/2017)
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include MediciNova (MNOV), Arbutus Biopharma (ABUS), Aquinox Pharmaceuticals (AQXP), Syros Pharmaceuticals (SYRS), Kala Pharmaceuticals (KALA), Paratek Pharmaceuticals (PRTK), Innate Pharma (IPHYF), Minerva Neurosciences (NERV), Corbus Pharmaceuticals (CRBP), Clearside Biomedical (CLSD), Bellicum Pharmaceuticals (BLCM), Catalyst Pharmaceuticals (CPRX), Sienna Biopharmaceuticals (SNNA), DURECT (DRRX) and Corium International (CORI).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Ms. Sara M. Bonstein, Exec. VP, Principal Accounting Officer, CFO & Corp. Sec. (Age 37)
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 58)
- Mr. Anthony A. Lombardo, Interim Chief Exec. Officer (Age 69)
- Mr. Christopher Duke, Sr. VP & COO
- Mr. Mayo Pujols, Sr. VP of Technical Operations
Has Advaxis been receiving favorable news coverage?
Press coverage about ADXS stock has been trending somewhat negative on Sunday, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Advaxis earned a news sentiment score of -0.04 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 48.87 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Advaxis' major shareholders?
Advaxis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.59%) and DAFNA Capital Management LLC (1.33%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.
Which institutional investors are buying Advaxis stock?
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $1.63.
How big of a company is Advaxis?
Advaxis has a market capitalization of $89.46 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Advaxis employs 108 workers across the globe.
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (ADXS)
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
